JP2000505465A - アポトーシスの刺激のためのat▲下1▼レセプターアンタゴニスト - Google Patents
アポトーシスの刺激のためのat▲下1▼レセプターアンタゴニストInfo
- Publication number
- JP2000505465A JP2000505465A JP9530554A JP53055497A JP2000505465A JP 2000505465 A JP2000505465 A JP 2000505465A JP 9530554 A JP9530554 A JP 9530554A JP 53055497 A JP53055497 A JP 53055497A JP 2000505465 A JP2000505465 A JP 2000505465A
- Authority
- JP
- Japan
- Prior art keywords
- apoptosis
- receptor antagonist
- treatment
- prevented
- stopped
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.アポトーシスを刺激するための、およびアポトーシスにより実質的に軽減 、停止または予防される病理的症状を処置するための医薬製剤を製造するための AT1レセプターアンタゴニストまたは製薬学的に使用できるその塩の使用。 2.アボトーシスを刺激するための、およびアポトーシスにより実質的に軽減 、停止または予防される病理的症状を処置するためのAT1レセプターアンタゴ ニストまたは製薬学的に使用できるその塩を含む医薬製剤。 3.治療的に有効な量のAT1レセプターアンタゴニストまたは製薬学的に使 用できるその塩を投与することを含む、アポトーシスを刺激するための、および アポトーシスにより実質的に軽減、停止または予防される病理的症状を処置する ための方法。 4.アポトーシスを刺激するための、およびアポトーシスにより実質的に軽減 、停止または予防される病理的症状を処置するためのAT1レセプターアンタゴ ニストまたは製薬学的に使用できるその塩の使用。 5. またはそれぞれの製薬学的に利用できるそれらの塩からなる群から選択される化 合物がAT1レセプターアンタゴニストとしての使用に適しているものである、 請求項1または4に記載の使用。 6. またはそれぞれの製薬学的に利用できるそれらの塩からなる群から選択されるA T1レセプターアンタゴニストの治療的有効量を使用する、アポトーシスにより 実質的に軽減、停止または予防される病理的症状を処置するための請求項3記載 の方法。 7.妨害を受けない細胞増殖の抑制、子宮内膜症、前立腺肥大、肥満、免疫抑 制疾患および再狭窄の処置、ならびに化学療法または放射線療法の耐性の達成の ための医薬製剤を製造するための、請求項1または5に記載のAT1レセプター アンタゴニストの使用。 8.妨害を受けない細胞増殖の抑制、子宮内膜症、前立腺肥大、肥満、免疫抑 制疾患および再狭窄の処置、ならびに化学療法または放射線療法の耐性の達成の ための医薬製剤を製造するための、医薬製剤を製造するための、請求項2に記載 の医薬製剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH52296 | 1996-02-29 | ||
CH522/96 | 1996-02-29 | ||
PCT/EP1997/000757 WO1997031634A1 (en) | 1996-02-29 | 1997-02-18 | At1 receptor antagonist for the stimulation of apoptosis |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2000505465A true JP2000505465A (ja) | 2000-05-09 |
JP2000505465A5 JP2000505465A5 (ja) | 2004-11-25 |
JP4369994B2 JP4369994B2 (ja) | 2009-11-25 |
Family
ID=4188936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53055497A Expired - Fee Related JP4369994B2 (ja) | 1996-02-29 | 1997-02-18 | アポトーシスの刺激のためのat▲下1▼レセプターアンタゴニスト |
Country Status (11)
Country | Link |
---|---|
US (1) | US6174910B1 (ja) |
EP (1) | EP0883401B1 (ja) |
JP (1) | JP4369994B2 (ja) |
AT (1) | ATE230263T1 (ja) |
AU (1) | AU1791497A (ja) |
CY (1) | CY2456B1 (ja) |
DE (1) | DE69718146T2 (ja) |
DK (1) | DK0883401T3 (ja) |
ES (1) | ES2189940T3 (ja) |
PT (1) | PT883401E (ja) |
WO (1) | WO1997031634A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007091758A (ja) * | 2000-06-22 | 2007-04-12 | Novartis Ag | 固体バルサルタン医薬組成物 |
JPWO2005087267A1 (ja) * | 2004-03-12 | 2008-01-24 | よこはまティーエルオー株式会社 | 前立腺肥大症治療剤 |
JP2013166802A (ja) * | 2007-04-13 | 2013-08-29 | Southern Research Inst | 血管新生阻害薬及び使用方法 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1013273A1 (en) * | 1998-12-23 | 2000-06-28 | Novartis AG | Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors |
US6465502B1 (en) * | 1998-12-23 | 2002-10-15 | Novartis Ag | Additional therapeutic use |
CZ293257B6 (cs) * | 1998-12-23 | 2004-03-17 | Novartis Ag | Farmaceutický přípravek obsahující antagonistu receptoru AT1 pro léčení nemocí spojených s nárůstem receptorů AT1 v subepiteliální vrstvě |
DE10153737A1 (de) * | 2001-10-31 | 2003-05-28 | Boehringer Ingelheim Pharma | Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels |
EP1750862B1 (en) * | 2004-06-04 | 2011-01-05 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1334092C (en) | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
ATE250587T1 (de) | 1989-06-14 | 2003-10-15 | Smithkline Beecham Corp | Imidazoalkensäure |
US5298518A (en) | 1989-09-29 | 1994-03-29 | Eisai Co., Ltd. | Biphenylmethane derivative and pharmacological use |
DE122007000050I1 (de) | 1990-02-19 | 2007-11-08 | Novartis Ag | Acylverbindungen |
NZ237476A (en) | 1990-03-20 | 1994-01-26 | Sanofi Sa | N-substituted heterocyclic compounds and pharmaceutical compositions. |
US5196444A (en) | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
US5250548A (en) * | 1990-09-10 | 1993-10-05 | Abbott Laboratories | Angiotensin II receptor antagonists |
IL99246A0 (en) | 1990-09-10 | 1992-07-15 | Abbott Lab | Angiotensin ii receptor antagonists and pharmaceutical compositions containing them |
US5591762A (en) | 1991-02-06 | 1997-01-07 | Dr. Karl Thomae Gmbh | Benzimidazoles useful as angiotensin-11 antagonists |
GB9110636D0 (en) | 1991-05-16 | 1991-07-03 | Glaxo Group Ltd | Chemical compounds |
DK0636027T3 (da) | 1992-04-13 | 2000-01-31 | Zeneca Ltd | Angiotensin-II-antogonister mod sygdomme forbundet med forringet neuronal ledningshastighed, især diabetisk neuropati |
EP0635263A3 (en) * | 1993-06-28 | 1995-09-27 | American Cyanamid Co | Angiotensin II antagonists (AII) as inhibitors of the growth of adipose tissue. |
JPH09510225A (ja) * | 1994-03-17 | 1997-10-14 | チバ−ガイギー アクチェンゲゼルシャフト | バルサルタンを用いる糖尿病性ネフロパシーの治療 |
US5981470A (en) * | 1994-06-07 | 1999-11-09 | The University Of Birmingham | Uterine fibroid treatment |
-
1997
- 1997-02-18 DE DE69718146T patent/DE69718146T2/de not_active Expired - Lifetime
- 1997-02-18 WO PCT/EP1997/000757 patent/WO1997031634A1/en active IP Right Grant
- 1997-02-18 AT AT97903313T patent/ATE230263T1/de active
- 1997-02-18 JP JP53055497A patent/JP4369994B2/ja not_active Expired - Fee Related
- 1997-02-18 EP EP97903313A patent/EP0883401B1/en not_active Expired - Lifetime
- 1997-02-18 AU AU17914/97A patent/AU1791497A/en not_active Abandoned
- 1997-02-18 PT PT97903313T patent/PT883401E/pt unknown
- 1997-02-18 US US09/142,003 patent/US6174910B1/en not_active Expired - Lifetime
- 1997-02-18 DK DK97903313T patent/DK0883401T3/da active
- 1997-02-18 ES ES97903313T patent/ES2189940T3/es not_active Expired - Lifetime
-
2004
- 2004-06-04 CY CY0400043A patent/CY2456B1/xx unknown
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007091758A (ja) * | 2000-06-22 | 2007-04-12 | Novartis Ag | 固体バルサルタン医薬組成物 |
JPWO2005087267A1 (ja) * | 2004-03-12 | 2008-01-24 | よこはまティーエルオー株式会社 | 前立腺肥大症治療剤 |
JP2013166802A (ja) * | 2007-04-13 | 2013-08-29 | Southern Research Inst | 血管新生阻害薬及び使用方法 |
Also Published As
Publication number | Publication date |
---|---|
ES2189940T3 (es) | 2003-07-16 |
DE69718146D1 (de) | 2003-02-06 |
DK0883401T3 (da) | 2003-05-05 |
EP0883401A1 (en) | 1998-12-16 |
ATE230263T1 (de) | 2003-01-15 |
US6174910B1 (en) | 2001-01-16 |
AU1791497A (en) | 1997-09-16 |
JP4369994B2 (ja) | 2009-11-25 |
WO1997031634A1 (en) | 1997-09-04 |
DE69718146T2 (de) | 2003-10-02 |
CY2456B1 (en) | 2005-06-03 |
PT883401E (pt) | 2003-03-31 |
EP0883401B1 (en) | 2003-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Schelling et al. | Angiotensin and cell growth: a link to cardiovascular hypertrophy? | |
JP6087836B2 (ja) | 併用療法 | |
Kim et al. | Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats. | |
JP4119746B2 (ja) | TAFIa阻害剤としての置換されたイミダゾール | |
JP2002533404A (ja) | 新生物形成の治療における組合わせ療法としてインテグリン拮抗剤及び放射線治療を使用する方法 | |
TW200804312A (en) | Novel triazole derivatives as Ghrelin analogue ligands of growth hormone secretagogue receptors | |
JPH03169866A (ja) | 置換n―(イミダゾリル)アルキルアラニン誘導体 | |
JP2000505465A (ja) | アポトーシスの刺激のためのat▲下1▼レセプターアンタゴニスト | |
US10835516B2 (en) | Protective, anti-inflammatory receptor and its use in preservation of mitochondrial function, wound healing and repair | |
JP2006516571A (ja) | 良性前立腺増殖症の処置 | |
JP2023145479A (ja) | アンドロゲン除去療法随伴症状の治療 | |
CN110325523B (zh) | 作为缓激肽b1受体拮抗剂的羧酸芳族酰胺 | |
CN113795273A (zh) | 基于胶原肽的药物组合物和装置及其生产方法和用途 | |
TW445147B (en) | Pharmaceutical composition for preventing and treating postischemic renal failure and for protecting the ischemic kidney, comprising an AT1-receptor antagonist | |
JPH11503139A (ja) | ベナゼプリルまたはベナゼプリラートおよびバルサルタンを含有する組み合わせ組成物 | |
JP2001504804A (ja) | Fas発現阻害方法 | |
JP2022505033A (ja) | ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法 | |
JPWO2011162390A1 (ja) | 徐放性高血圧および腎機能障害治療剤 | |
US20200347136A1 (en) | Constrained cyclic peptides as inhibitors of the cd2:cd58 protein-protein interaction for treatment of diseases and autoimmune disorders | |
JP2001518062A (ja) | 肺繊維症の治療 | |
JPWO2019074116A1 (ja) | Axl阻害剤を有効成分として含む固形がん治療剤 | |
KR101530019B1 (ko) | 혈관성형술 또는 동맥내막절제술 후 재협착 및 장기 섬유증으로 인한 질환의 치료에 유용한 5베타, 14베타-안드로스테인 유도체 | |
WO2012047763A2 (en) | Stimulation of neuroregeneration by flavonoid glycosides | |
Pham et al. | What can angiotensin antagonists do that converting-enzyme inhibition can't: the case of post-angioplastic restenosis | |
JPH06157311A (ja) | 血管病変治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040205 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040205 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070220 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070328 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070521 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070817 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090217 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090511 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090622 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090615 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090818 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090831 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120904 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130904 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |